Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapy.
Curr Pharm Biotechnol
; 9(3): 231-4, 2008 Jun.
Article
en En
| MEDLINE
| ID: mdl-18673289
ABSTRACT
Ribonucleases (RNases) of the superfamily A exhibit potent antineoplastic activity yet do not mediate appreciable immunogenicity or non-specific toxicity in both animal models and cancer patients. Ranpirnase (Onconase), the first ribonuclease being evaluated as a therapeutic in humans, has progressed to phase III clinical trials in patients with unresectable mesothelioma. Conjugation of RNases to internalizing tumor-targeting monoclonal antibodies was shown to enhance specific cell killing by several orders of magnitude both in vitro and in animal models. In this review we describe the development and current status of genetically engineered 2(nd) generation immunoRNases as promising novel anti-cancer therapeutics.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Ribonucleasa Pancreática
/
Proteínas Recombinantes de Fusión
/
Inmunoconjugados
/
Anticuerpos Monoclonales
/
Neoplasias
/
Antineoplásicos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Pharm Biotechnol
Asunto de la revista:
BIOTECNOLOGIA
/
FARMACOLOGIA
Año:
2008
Tipo del documento:
Article
País de afiliación:
Alemania